WiseGuyReports published new report, titled “Global Dengue Vaccine Market Outlook”.
Dengvaxia (CYD-TDV), first dengue vaccine is a live recombinant tetravalent dengue vaccine that is indicated as a 3 dose series of 0/6/12 month schedule invented by Sanofi Pasteur. CYD-TDV and DENVax are expected to lose market share to the domestically-produced live-attenuated vaccine, TV-003 due to its lower price. Today dengue resides in 125 countries around the world and Aedes aegypti, the primary vector is everywhere, making transmission reduction is the major area of concern.
According to WHO, number of deaths caused by dengue virus was 297, 873 in 2012 and 159 per million in low income, lower-middle income and upper-middle income regions. The global market for dengue vaccines holds the opportunities for drugmakers when the will be able to successfully develop effective vaccines for all age group. The major growth driver of global dengue vaccine market is the process of urbanization.
Merger & acquisition is the key strategy for the vendors of dengue market, for instance, Sanofi “Be a Wall against Dengue” disease education campaign to raise awareness on dengue prevention in Singapore, launched under partnership of Pasteur and Ya Kun Kaya Toast in conjunction with ASEAN Dengue Day (15 June 2017). Similarly, Takeda pharmaceutical company and Biological E. limited entered into a partnership for the development and delivery of low-cost combination vaccines. There are 5 vaccines in Phase I-III and 4 first-in-class vaccines in pipeline assessment.
- By Technology
o Live attenuated vaccine
o Chimeric Live attenuated vaccine
o Subunit vaccine
o Inactivated vaccine
o Nucleic acid based vaccine
- By End Users
o Diagnostic Labs
o Government Institutes
o Others (retail pharmacies, online pharmacies, etc)
Market Drivers and Challenge
The key driving factors of global dengue market are increasing dengue fever occurrence, promising end stage vaccine pipeline, local production of dengue vaccines and innovation of live attenuated tetravalent dengue vaccine. However, less number of skilled professionals and unavailability of optimum diagnostic systems where dengue fever is visualized as a common febrile disease have driven the global dengue vaccine market.
Unplanned and uncontrolled urbanization, stiff competition among existing players, high possibilities of side effects, lack of basic amenities in communities, poor environmental management, and climatic change hinders the global dengue vaccine market. In addition, supply side infrastructure bottlenecks such as surveillance system, standardized diagnostics practice, and cold chain systems for storage of vaccine in resource constrained countries are the restraints responsible for the decline of global dengue vaccine market.
Key Market Players
- Sanofi Pasteur
o Business Strategy
o Product Portfolio
o SWOT Analysis
• Biological E. Limited
• Merck & Co.
• Panacea Biotech Ltd.
• Butantan Institute
The Global Dengue Vaccine Market is segmented as follows:
• By Technology (Market Size, Demand Analysis and Growth Analysis)
• By End-User (Market Size, Demand Analysis and Growth Analysis)
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Email Us at : firstname.lastname@example.org
Reach Us at : +1 339 368 6938 (US) +44 208 133 9349 (US)
For accessing accurate and deep understanding and to gain latest insights and key developments in the area of your interest, we also have a list of conferences in which you will be interested in, for more information, cordially check
For updating knowledge or for thoroughly understanding various terminologies, we also have vast list of seminars for your reference, for more information cordially check